Menu

Infographic: Evolving Virulence

Tracking the myxoma virus in the wild rabbit populations of Australia has yielded insight into how pathogens and their hosts evolve.

Sep 30, 2017
Andrew F. Read and Peter J. Kerr

When a pathogen jumps species, it is often highly lethal in its new host. But a quick kill does not make for continued transmission; the host must survive long enough to pass the pathogen on to additional victims. Thus, under natural conditions, a newly emergent, highly lethal pathogen that kills very rapidly is expected to evolve lower virulence. At the same time, however, the host species is evolving resistance to the infection, which then provides an environment for increasing pathogen virulence. Could humans be creating a similar environment by vaccinating or breeding our farm animals to resist disease?

Wild rabbit populations in Australia declined dramatically in the early 1950s after the release of the myxoma virus, which caused a fatal disease called myxomatosis. Slowly, the populations started to rebound, though they never fully recovered.

To track the myxoma virus (MYXV) as it devastated the invasive rabbit populations of Australia, researchers conducted what are known as common garden experiments, testing the effects of the evolving viral strains on laboratory rabbits, as well as the effects of a standard virus on different samples of rabbits in the wild over time.

When MYXV first infected the Australian rabbit population in 1950, it caused a severe disease known as myxomatosis that killed more than 99 percent of its victims. Natural selection favored strains with reduced lethality and therefore longer infectious periods. Within a few years, circulating viruses had fatality rates between 95 percent and less than 50 percent.

Meanwhile, the rabbits were evolving resistance to the viral infection, though the protection was not complete, allowing the virus to continue evolving.

Host resistance likely decreased the virus’s transmission rate, thus setting the stage for the selection of more virulent strains. Sometime between the mid-1970s and the early 1980s, strains arose that massively suppressed the cellular inflammatory response of laboratory rabbits. In wild rabbits, the combination of host resistance and increased viral virulence resulted in typical myxomatosis presentation, but when naive rabbits were exposed to the new viral strains, bacterial infections bloomed in their immunosuppressed bodies, killing nearly all of the hosts before they developed the classic disease.

Read the full story.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!